Changes for clozapine monitoring in the United States

Tarun Bastiampillai, Arun Gupta, Sherry Chan, Robert Allison

    Research output: Contribution to journalComment/debate

    6 Citations (Scopus)

    Abstract

    Clozapine is a unique compound that is particularly effective for treatment-resistant schizophrenia (TRS). The use of clozapine is limited, however, due to the 0.8% risk of agranulocytosis,1 which necessitates a strict monitoring of neutrophil counts to detect early neutropenia and prevent progression to agranulocytosis. The US Food and Drug Administration (FDA) in 2015 allowed greater flexibility to continue or re-challenge clozapine in patients who have experienced neutropenia on clozapine.2 Lithium and granulocyte-colony stimulating factor (G-CSF) have been used as preventative therapies for patients with a history of clozapine-induced neutropenia upon clozapine re-challenge.
    Original languageEnglish
    Pages (from-to)858-860
    Number of pages3
    JournalMOLECULAR PSYCHIATRY
    Volume21
    Issue number7
    DOIs
    Publication statusPublished - Jul 2016

    Keywords

    • United States
    • monitoring
    • clozapine
    • treatment-resistant schizophrenia (TRS)
    • treatment-resistant
    • schizophrenia

    Fingerprint Dive into the research topics of 'Changes for clozapine monitoring in the United States'. Together they form a unique fingerprint.

    Cite this